14-3-3 η (Eta) Protein as a Marker of Disease Activity, Severity and Subclinical Atherosclerosis in Patients With Rheumatoid Arthritis.
Status: Unknown
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY
The aims of this study are: • To assess 14-3-3 η (eta) protein antibodies in the serum of rheumatoid arthritis patients and its relation to disease activity and severity. • To investigate the role of 14-3-3 η (eta) protein in the diagnosis or assessment of subclinical carotid artery atherosclerosis.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 50
Healthy Volunteers: t
View:
⁃ Patients with RA classified according to the revised American College of Rheumatology (ACR)/EULAR RA classification criteria 2010 for RA.
• Age ≥ 18 years.
• Patients who are able and willing to give written informed consent.
• Disease duration more than one year
Contact Information
Primary
doaa adel, specialist
doaa_adel_post@med.sohag.edu.eg
01201786669
Time Frame
Start Date: 2021-09
Completion Date: 2022-09
Participants
Target number of participants: 140
Treatments
rheumatoid arthritis patients
90 RA patients diagnosed according to the American college of rheumatology (ACR) -EULAR RA classification criteria 2010
control group
50 age and sex matched healthy controls. All
Related Therapeutic Areas
Sponsors
Leads: Sohag University